361 Capital’s Emergent Biosolutions EBS Stock Holding History

361 Capital’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-18,555	Closed	-$1.07M	–	329
2020 Q1	$1.07M	Sell	18,555 -4,401	-19%	-$254K	0.49%	44
2019 Q4	$1.24M	Buy	+22,956	New	+$1.25M	0.34%	152
2019 Q2	–	Sell	-23,895	Closed	-$1.21M	–	333
2019 Q1	$1.21M	Buy	+23,895	New	+$1.41M	0.21%	193
2018 Q3	–	Sell	-30,556	Closed	-$1.54M	–	352
2018 Q2	$1.54M	Buy	30,556 +1,009	+3%	+$52.6K	0.35%	167
2018 Q1	$1.56M	Sell	29,547 -23,115	-44%	-$1.15M	0.39%	91
2017 Q4	$2.45M	Buy	52,662 +47,637	+948%	+$2.01M	0.61%	36
2017 Q3	$203K	Buy	+5,025	New	+$182K	0.04%	241

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

361 Capital's EBS Position: Q2 2020 in Review

361 Capital sold out of Emergent Biosolutions (EBS) in Q2 2020, closing a stake of 18,555 shares — an estimated $1.07M sold.

361 Capital first reported a position in EBS in Q3 2017 and held it in 7 quarters. The position peaked at $2.45M in Q4 2017. 299 funds tracked by Wall St. Rank hold EBS as of Q2 2020.

361 Capital reported no remaining Emergent Biosolutions position as of Q2 2020 after selling out during the quarter.
361 Capital sold 18,555 Emergent Biosolutions shares in Q2 2020, an estimated $1.07M.
361 Capital first reported a position in Emergent Biosolutions in Q3 2017 and held it in 7 quarters.
361 Capital's Emergent Biosolutions position peaked at $2.45M in Q4 2017.
299 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.